Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined GA and Bilateral TPVB in OPCAB
NCT02727712Phase 4
Key facts
- Status
- Unknown
- Start
- Apr 2016
- Primary completion
- Sep 2016
- Countries
- 1
- Sponsor
- Xiangya Hospital, Central South University
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Conditions
- pain
01
Overview
Phase 4, randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in pain (3 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Fasting blood glucose at 4 days, Blood Lactic Acid at 4 days and 6 more. Status: unknown.
02
Design
3 arms- Study design
- RandomizedDouble-blind
TPVB T2/3+T5/6+GA
Bilateral TPVB (T2/3+T5/6) with ropivacaine + General Anesthesia
TPVB T3/4+GA
Bilateral TPVB (T3/4) with ropivacaine + General Anesthesia
GA
Conventional General Anesthesia without block
03
Endpoints
Primary
Fasting blood glucose
Blood Lactic Acid
Creatine kinase isoenzymes
Myoglobin
Troponin I
Secondary
Perioperative major adverse events
Perioperative use of vasoactive drug species
Vasoactive drugs Support Hours
Postoperative tracheal tube time
Duration of mechanical ventilation after surgery
Length of ICU stay
The total length of hospital stay
Visual analog pain score
Beyond the preview
Go deeper on NCT02727712.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02727712.